Thirty-six beef calves were used to test the efficacy of an experimental truncated BHV-1 glycoprotein (tgIV) vaccine. Calves from 1 source and +/- 1 mo of age were randomly divided into 4 groups: 1) control (adjuvant VSA3), 2) vaccinated with tgIV at 3 and 4 mo of age, 3) vaccinated with tgIV at 3 and 7 mo of age, or 4) vaccinated with tgIV at 6 and 7 mo of age. Calves were challenged with BHV-1 in aerosol (strain 108) at 7 1/2 mo of age. Prior to challenge, serum neutralizing (SN) antibody titers to BHV-1 were significantly (P < 0.05) higher in all vaccinated calves than in controls. Calves vaccinated at 3 and 7, or 6 and 7, mo of age had significantly (P < 0.05) higher SN antibody and nasal antibody titers to BHV-1 and ELISA (enzyme linked immunosorbent assay) titers to gIV at prechallenge than those vaccinated at 3 and 4 mo of age or controls. Postchallenge nasal shedding of BHV-1 occurred only in controls and those vaccinated at 3 and 4 mo of age. Control calves lost significantly (P < 0.05) more weight and had higher sick scores after challenge than those vaccinated at 3 and 7, or at 6 and 7, mo of age. There were strong correlations (P < 0.001) between antibody titers, virus shedding, and sickness.